News

The company said that this next Phase IIa dose expansion trial is a multicenter, randomized, open-label, controlled study, which is expected to be completed in the fourth quarter

VTU Technology currently offers a very broad and comprehensive Pichia pastoris expression platform and the deal grants Biomay access to VTU’s Pichia pastoris protein expression technology. Under the

Under the deal, CMS has secured exclusive assets and rights for the development and commercialisation of Faron’s lead drug candidate traumakine in China, Hong Kong, Macao and Taiwan

The company said that the updated breakthrough therapy designation reflects recently presented data on HCV genotype 1 patients with advanced cirrhosis (Child-Pugh Class B or C) and those

Currently, Revusiran is being evaluated in a Phase III trial to treat Familial Amyloidotic Cardiomyopathy (FAC), one of the predominant clinical manifestations of ATTR amyloidosis. Patient enrollment is

In Japan, Lenvima is the first molecular targeted treatment approved with an indication for unresectable thyroid cancer which covers differentiated thyroid cancer as well as medullary thyroid carcinoma

This study demonstrated that Latuda (lurasidone HCl) significantly reduced depressive symptoms in adults with MDD with mixed features when compared to placebo. The study results were presented at

The Muscle Maker Grill booster supplements are intended to meet the growing consumer demand for customized smoothies and protein shakes as well as help Muscle Maker Grill franchisees

"Emergent is pleased to enter into this agreement, which reflects our leading capabilities in plasma fractionation and fits perfectly with ProMetic’s proprietary plasma purification platform," said Barry Labinger,